Strategic alliance deal between Dabur Oncology and Abbot Laboratories potentially worth US$20 million
Represented Dabur Oncology Plc in its strategic alliance deal with Abbot Laboratories Inc. to develop, manufacture and market prescription generic oncology products in the United States in 2002. Performance based milestones to Dabur of more than US$20 million could be payable, plus profit share of sales in a market estimated to be worth US$15 billion by 2010.